Open AccessTranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen
Author(s) -
Angela Jerath,
Quan Yang,
K. Sandy Pang,
Nikita Looby,
Nathaly ReyesGarcés,
Tijana Vasiljević,
Barbara Bojko,
Janusz Pawliszyn,
Duminda N. Wijeysundera,
W. Scott Beattie,
Terrence M. Yau,
Marcin Wąsowicz
Publication year - 2018
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000002724
Subject(s) - medicine , tranexamic acid , dosing , regimen , anesthesia , antifibrinolytic , bolus (digestion) , surgery , blood loss
Tranexamic acid (TXA) is a common antifibrinolytic agent used to minimize bleeding in cardiac surgery. Up to 50% cardiac surgical patients have chronic renal dysfunction (CRD). Optimal dosing of TXA in CRD remains poorly investigated. This is important as TXA is renally eliminated with accumulation in CRD. High TXA doses are associated with postoperative seizures. This study measures plasma TXA concentrations in CRD cardiac surgical patients for pharmacokinetic modeling and dose adjustment recommendations.